Creative Medical Technology Holdings Aktie [ISIN: US22529Y2000]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Creative Medical Technology Holdings Inc Registered Shs

07.03.24		Creative Medical Announces FDA Authorization For Expanded Access For CELZ-201; Stock Up (RTTNews)
06.03.24		Creative Medical Receives FDA Orphan Drug Designation For CELZ-101; Stock Up In Pre-market (RTTNews)
15.11.23		Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
10.10.23		Creative Medical Gets IRB Approval For StemSpine Trial Using AlloStem Cell Therapy (RTTNews)
10.10.23		Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain (PR Newswire)
19.09.23		Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain (PR Newswire)
28.07.23		Pre-market Movers: SIGA, SNBR, BLUA, SNTG, PRZO… (RTTNews)
29.06.23		Pre-market Movers: SGTX, WAVE, BTAI, KTRA, CRMD… (RTTNews)
28.06.23		Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements (PR Newswire)
16.06.23		Pre-market Movers: SPCE, IRBT, BMR, COMS, FNGR… (RTTNews)
12.06.23		Creative Medical Technology Announces $2 Million Share Repurchase Program (PR Newswire)
12.06.23		Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
09.06.23		Creative Medical Technology Holdings Announces Reverse Stock Split (PR Newswire)
31.05.23		Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immun... (PR Newswire)
22.05.23		Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development (PR Newswire)
18.05.23		Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line (PR Newswire)
12.04.23		Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study (PR Newswire)
04.04.23		Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update (PR Newswire)
23.03.23		Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes (PR Newswire)
21.03.23		Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development (PR Newswire)
08.02.23		Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire)
03.11.22		Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire)
20.10.22		Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line (PR Newswire)
26.09.22		Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study (PR Newswire)
28.07.22		Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study (PR Newswire)
15.06.22		Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform (PR Newswire)
29.04.22		Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
20.04.22		Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product (PR Newswire)
12.04.22		Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World (PR Newswire)
31.03.22		Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform (PR Newswire)
23.03.22		Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study (PR Newswire)
10.03.22		Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction (PR Newswire)
08.03.22		Creative Medical Technology to Participate in the 34th Annual Roth Conference (PR Newswire)
02.03.22		Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer (PR Newswire)
22.02.22		Pre-market Movers: DWAC, SKYH, LLL, OCGN, ANGH… (RTTNews)
18.02.22		Pre-market Movers: NRGV, ROKU, RDFN, CELZ, SHAK… (RTTNews)
05.01.22		Pre-market Movers: MYNZ, WEJO, ANNX, ARAV, SENS… (RTTNews)
04.01.22		Pre-market Movers: IMMX, VALN, LQDA, OSAT, EKSO… (RTTNews)
03.01.22		Pre-market Movers: CELZ, AFI, BLCT, AGE, PTE… (RTTNews)
07.12.21		Pre-market Movers: BJDX, MDB, CELZ, ISIG, ACAD… (RTTNews)
03.12.21		Creative Medical Prices $16 Mln Public Offering At $4.13 (RTTNews)
03.12.21		Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market (PR Newswire)
09.11.21		Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market (PR Newswire)
12.10.21		Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product (PR Newswire)
01.10.21		Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform (PR Newswire)
16.09.21		Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem® (PR Newswire)
09.08.21		Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors (PR Newswire)
20.07.21		Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product (PR Newswire)
22.06.21		Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance (PR Newswire)
17.06.21		Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 15:46
Kaufwert:	EUR
	Hinzufügen Speichern